查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566752

人造器官与医疗仿生市场：按类型、技术：2024-2033 年全球机会分析与产业预测

Artificial Vital Organs and Medical Bionics Market By Type (Artificial Organs, Medical Bionics) , By Technology (Mechanical, Electronic) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年，人造器官和医疗仿生市场价值为474亿美元，预计到2033年将达到990亿美元，2024年至2033年的复合年增长率为7.6%。

人造器官是指当自然器官受损、发生故障或丧失功能时替代或模仿自然器官功能的医疗设备。这些设备旨在恢復失去的功能、增强人类能力并提高整体生活品质。另一方面，仿生植入是植入或附着在身体上以增强或恢復特定功能的电子或机械装置。开拓基于仿生原理製造人体器官的生物人工器官製造技术，是人工生命器官和医学仿生市场的重要里程碑。

儘管药物、介入和手术治疗取得了进步，但器官衰竭病例的惊人增加推动了全球人造器官和医学仿生学市场的成长。严重的器官功能障碍不仅可能由受伤或疾病引起，也可能由视力或听力丧失等非危及生命的疾病引起，这会降低生活品质并增加对人工重要器官的需求。此外，移植供体器官的短缺是全球市场的主要驱动力。根据器官移植网络 2024 年 3 月的统计数据，根据与美国卫生与公众服务部签订的合约运营的器官移植网络 (UNOS) 已为全美约 103,223 名男性、女性和婴儿提供了移植手术我在等候名单上。据同一消息来源称，每天有 17 人在等待器官移植过程中死亡。此外，老年人口的快速成长是全球市场的主要驱动力。这是由于对人造器官解决方案的需求增加，因为老年人更容易因慢性疾病和功能障碍而出现器官衰竭，限制了他们执行日常家务的能力。根据世界卫生组织（WHO）的数据，2019年60岁以上的人口有10亿人。预计到 2030 年，这一数字将增至 14 亿，到 2050 年将增至 21 亿，这可能会对市场成长做出重大贡献。因此，所有这些因素都显着促进了器官移植数量的增加。根据器官取得和移植网统计，2023年进行了超过4.6万例器官移植。此外，对人工器官移植的认识和接受度不断提高正在推动市场成长。导致创伤的事故案例不断增加，以及导致截肢的糖尿病和周围血管疾病盛行率的惊人上升，正在推动对医疗仿生学的需求。根据 ScienceDirect（世界领先的科学、技术和医学研究资讯来源）2020 年发表的一项研究，美国每年约有 30,000 至 40,000 例平民因受伤而进行截肢手术。为了满足截肢者不断增长的需求，製造商正在专注于开发先进的义肢，这些义肢配备了感测器和致动器来模仿真实肢体的自然运动和功能，从而大大提高了活动能力。然而，人工器官移植和医学仿生学的高成本、免疫排斥的风险以及伦理衝突是全球市场的主要阻碍因素。相反，人造器官的技术进步预计将为预测期内的市场扩张提供利润丰厚的机会。例如，製造商专注于提高人造器官的功能、监测能力和整体有效性，因此正在将生物电子和数位健康技术融入其中，这将有望彻底改变移植产业。

人造器官和医疗仿生学市场按类型、技术、最终用户和地区进行细分。根据类型，市场分为人造器官和医学仿生学。人工器官又分为人工心臟、人工肾臟、人工肺臟等。医学仿生学又分为整形外科仿生学和其他仿生学。在技​​术基础上，市场分为机械市场和电子市场。依最终用户划分，可分为医院、门诊手术中心等。从区域来看，我们对北美、欧洲、亚太地区和拉丁美洲/中东/非洲的市场进行了分析。

主要发现

按类型划分，预计到 2033 年，人造器官细分市场将占据市场主导地位。

从技术角度来看，机械领域预计将在预测期内呈现最高成长。

对于最终用户来说，医院领域预计将在未来几年受到高度关注。

按地区划分，北美是 2023 年的主要收益来源，在预测期内也可能主导市场。

可以使用此报告进行客製化（需要额外费用和时间表）

  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析 – 市场规模和预测

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章人造器官与医疗仿生市场：依类型

  • 市场概况
  • 人造器官
    • 人工心臟
    • 人工肾
    • 人工肺
    • 其他的
  • 医学仿生学
    • 整形外科仿生学
    • 其他的

第五章人造器官与医疗仿生市场：依技术分类

  • 市场概况
  • 机械的
  • 电子产品

第六章 人造器官与医疗仿生市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国人造器官与医学仿生市场
    • 加拿大人造器官与医学仿生市场
    • 墨西哥人造器官与医疗仿生市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国人造器官与医学仿生市场
    • 德国人造器官与医学仿生市场
    • 义大利人造器官与医学仿生市场
    • 西班牙人造器官与医学仿生市场
    • 英国人造器官与医学仿生市场
    • 其他欧洲人造器官和医学仿生市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国人造器官及医学仿生市场
    • 日本人造器官及医疗仿生市场
    • 印度人造器官和医学仿生市场
    • 韩国人造器官与医学仿生市场
    • 澳洲人造器官与医学仿生市场
    • 其他亚太人造器官及医学仿生市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西人造器官与医学仿生市场
    • 南非的人造器官和医疗仿生市场
    • 沙乌地阿拉伯的人造器官和医疗仿生市场
    • 其他拉丁美洲、中东和非洲人造器官和医疗仿生市场

第七章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第八章 公司简介

  • SynCardia Systems LLC
  • Abbott Laboratories, Inc.
  • Cochlear Limited
  • Boston Scientific Corporation
  • Johnson And Johnson
  • Edwards Lifesciences Corporation
  • Zimmer Biomet Holding Inc.
  • Berlin Heart GmbH
  • Jarvik Heart, Inc.
  • Medtronic Plc.
简介目录
Product Code: A00270

The artificial vital organs and medical bionics market was valued at $47.4 billion in 2023, and is projected to reach $99.0 billion by 2033, growing at a CAGR of 7.6% from 2024 to 2033.

Artificial vital organs are medical devices that replace and mimic the functions of naturally occurring organs in individuals whose organs are damaged, dysfunctional, or impaired. These devices aim to restore lost functions, enhance human capabilities, and improve overall quality of life. Bionic implants, on the other hand, are electronic or mechanical devices that are implanted within or attached to the body to enhance or restore specific functions. The development of bioartificial organ manufacturing technologies to produce human organs based on bionic principles acts as a significant milestone in the artificial vital organs and medical bionics market.

The growth of the global artificial vital organs and medical bionics market driven by alarming increase in cases of organ failure, despite advancements in pharmacological, interventional, and surgical therapies. Serious organ dysfunction is not only caused due injuries or diseases but also due to nonlife-threatening disabilities such as loss of eyesight or hearing ability, which decreases the quality of life, thereby augmenting the demand for artificial vital organs. Moreover, shortage of donor organs for transplantation acts as a key driving force of the global market. According to the March 2024 statistics of the Organ Procurement and Transplantation Network-operated under contract with the U.S. Department of Health and Human Services by the United Network for Organ Sharing (UNOS)-approximately 103,223 number of men, women, and children are on the national transplant waiting list. As per the same source, 17 individuals die each day waiting for an organ transplant. Furthermore, surge in geriatric population acts as the key driving force of the global market. This is attributed to the fac that aged individuals are highly susceptible to chronic diseases and organ failure due to functional impairment that limit the ability to carry out day-to-day chores, thus boosting the demand for artificial organ solutions. As per the World Health Organization, the number of people aged 60 years and older was 1 billion in 2019. This number is estimated to increase to 1.4 billion by 2030 and 2.1 billion by 2050, which is likely to significantly contribute toward the market growth. Thus, all these factors substantially contribute to increase in number of organ transplants carried out. The statistics derived from Organ Procurement and Transplantation Network suggest that more than 46,000 organ transplants were performed in 2023. In addition, rise in awareness and acceptance of artificial organ transplants is driving the growth of the market. Increase in cases of accidents causing traumatic injuries and alarming rise in prevalence of diabetes and peripheral vascular diseases that lead to amputations are driving the demand for medical bionics. According to a study published in 2020 in ScienceDirect-the world's leading source for scientific, technical, and medical research-approximately 30,000 to 40,000 civilian injury-related amputations are performed every year in the U.S. To meet the growing demand of amputees, manufacturers are focusing on the development of advanced prosthetic limbs equipped with sensors and actuators mimic the natural movement and functionality of real limbs, significantly improving mobility. However, high cost associated with artificial organ transplants and medical bionics, risk of immune rejection, and ethical conflicts act as the key deterrent factors of the global market. On the contrary, technological advancements in artificial vital organs are expected to offer remunerative opportunities for the expansion of the market during the forecast period. For instance, manufacturers are focusing on enhancing the functionality, monitoring capabilities, and overall effectiveness of artificial organs; thus, they are integrating bioelectronics and digital health technologies into artificial organs, which is expected to revolutionize the organ transplant industry in the coming years.

The artificial vital organs and medical bionics market is segmented into type, technology, end user, and region. Depending on type, the market is categorized into artificial organs and medical bionics. The artificial organs is further segmented into artificial heart, artificial kidney, artificial lungs, and others. The medical bionics is further segmented into orthopedic bionics and others. On the basis of technology, the market is bifurcated into mechanical and electronic. As per end user, it is classified into hospitals, ambulatory surgical centers, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the artificial organs segment is expected to dominate the market by 2033.

On the basis of technology, the mechanical segment is anticipated to exhibit highest growth during the forecast period.

Depending on end user, the hospital segment is projected to gain high prominence in the coming years.

Region wise, North America was the major revenue generator in 2023, and is likely to dominate the market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global artificial vital organs and medical bionics market include SynCardia Systems LLC, Abbott Laboratories, Inc., Cochlear Limited, Boston Scientific Corporation, Johnson & Johnson, Edwards Lifesciences Corporation, Zimmer Biomet Holding Inc., Berlin Heart GmbH, Jarvik Heart, Inc., and Medtronic Plc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the competitive market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast

Key Market Segments

By Type

  • Artificial Organs
    • Artificial Heart
    • Artificial Kidney
    • Artificial Lungs
    • Others
  • Medical Bionics
    • Orthopedic Bionics
    • Others

By Technology

  • Mechanical
  • Electronic

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • SynCardia Systems LLC
    • Abbott Laboratories, Inc.
    • Cochlear Limited
    • Boston Scientific Corporation
    • Johnson & Johnson
    • Edwards Lifesciences Corporation
    • Zimmer Biomet Holding Inc.
    • Berlin Heart GmbH
    • Jarvik Heart, Inc.
    • Medtronic Plc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Artificial Organs
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
    • 4.2.5. Artificial Heart
      • 4.2.5.1. Market Size and Forecast
    • 4.2.6. Artificial Kidney
      • 4.2.6.1. Market Size and Forecast
    • 4.2.7. Artificial Lungs
      • 4.2.7.1. Market Size and Forecast
    • 4.2.8. Others
      • 4.2.8.1. Market Size and Forecast
  • 4.3. Medical Bionics
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country
    • 4.3.5. Orthopedic Bionics
      • 4.3.5.1. Market Size and Forecast
    • 4.3.6. Others
      • 4.3.6.1. Market Size and Forecast

CHAPTER 5: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY TECHNOLOGY

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Technology
  • 5.2. Mechanical
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Electronic
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country

CHAPTER 6: ARTIFICIAL VITAL ORGANS AND MEDICAL BIONICS MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By Technology
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Artificial Vital Organs and Medical Bionics Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By Technology
    • 6.2.6. Canada Artificial Vital Organs and Medical Bionics Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By Technology
    • 6.2.7. Mexico Artificial Vital Organs and Medical Bionics Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By Technology
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By Technology
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. France Artificial Vital Organs and Medical Bionics Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By Technology
    • 6.3.6. Germany Artificial Vital Organs and Medical Bionics Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By Technology
    • 6.3.7. Italy Artificial Vital Organs and Medical Bionics Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By Technology
    • 6.3.8. Spain Artificial Vital Organs and Medical Bionics Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By Technology
    • 6.3.9. UK Artificial Vital Organs and Medical Bionics Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By Technology
    • 6.3.10. Rest of Europe Artificial Vital Organs and Medical Bionics Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By Technology
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By Technology
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. China Artificial Vital Organs and Medical Bionics Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By Technology
    • 6.4.6. Japan Artificial Vital Organs and Medical Bionics Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By Technology
    • 6.4.7. India Artificial Vital Organs and Medical Bionics Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By Technology
    • 6.4.8. South Korea Artificial Vital Organs and Medical Bionics Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By Technology
    • 6.4.9. Australia Artificial Vital Organs and Medical Bionics Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By Technology
    • 6.4.10. Rest of Asia-Pacific Artificial Vital Organs and Medical Bionics Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By Technology
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By Technology
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Artificial Vital Organs and Medical Bionics Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By Technology
    • 6.5.6. South Africa Artificial Vital Organs and Medical Bionics Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By Technology
    • 6.5.7. Saudi Arabia Artificial Vital Organs and Medical Bionics Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By Technology
    • 6.5.8. Rest of LAMEA Artificial Vital Organs and Medical Bionics Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By Technology

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. SynCardia Systems LLC
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Abbott Laboratories, Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Cochlear Limited
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Boston Scientific Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Johnson And Johnson
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Edwards Lifesciences Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Zimmer Biomet Holding Inc.
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Berlin Heart GmbH
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Jarvik Heart, Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Medtronic Plc.
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments